Page 1665 - Williams Hematology ( PDFDrive )

1640 Part XI: Malignant Lymphoid Diseases <CN>: Diffuse Large B-Cell Lymphoma and Related Diseases PB

137. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al: Increased incidence of lymphop- 149. Aki H, Tuzuner N, Ongoren S, et al: T-cell-rich B-cell lymphoma: A clinicopathologic
roliferative disorder after immunosuppression with the monoclonal antibody OKT3 in study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. Leuk
cardiac-transplant recipients. N Engl J Med 323:25, 1990. Res 28:3, 2004.
138. Walker RC, Paya CV, Marshall WF, et al: Pretransplantation seronegative Epstein-Barr 150. Bouabdallah R, Mounier N, Guettier C, et al: T-cell/histiocyte-rich large B-cell lympho-
virus status is the primary risk factor for posttransplantation lymphoproliferative disor- mas and classical diffuse large B-cell lymphomas have similar outcome after chemo-
der in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant therapy: A matched-control analysis. J Clin Oncol 21:7, 2003.
14:2, 1995. 151. Boudova L, Torlakovic E, Delabie J, et al: Nodular lymphocyte-predominant Hodgkin
139. Hanto DW: Classification of Epstein-Barr virus-associated posttransplant lymphopro- lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: Differ-
liferative diseases: Implications for understanding their pathogenesis and developing ential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and
rational treatment strategies. Annu Rev Med 46:381, 1995. T-cell/histiocyte-rich B-cell lymphoma. Blood 102:10, 2003.
140. Leblond V, Davi F, Charlotte F, et al: Posttransplant lymphoproliferative disorders not 152. Greer JP, Macon WR, Lamar RE, et al: T-cell-rich B-cell lymphomas: Diagnosis and
associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 16:6, 1998. response to therapy of 44 patients. J Clin Oncol 13:7, 1995.
141. Kew CE 2nd, Lopez-Ben R, Smith JK, et al: Posttransplant lymphoproliferative disorder 153. McBride JA, Rodriguez J, Luthra R, et al: T-cell-rich B large-cell lymphoma simulating
localized near the allograft in renal transplantation. Transplantation 69:5, 2000. lymphocyte-rich Hodgkin’s disease. Am J Surg Pathol 20:2, 1996.
142. Rees L, Thomas A, Amlot PL: Disappearance of an Epstein-Barr virus-positive post- 154. Rodriguez J, Pugh WC, Cabanillas F: T-cell-rich B-cell lymphoma. Blood 82:5, 1993.
transplant plasmacytoma with reduction of immunosuppression. Lancet 352:9130, 1998. 155. Willemze R, Jaffe ES, Burg G, et al: WHO-EORTC classification for cutaneous lympho-
143. Tsai DE, Hardy CL, Tomaszewski JE, et al: Reduction in immunosuppression as ini- mas. Blood 105:10, 2005.
tial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic 156. Grange F, Beylot-Barry M, Courville P, et al: Primary cutaneous diffuse large B-cell
variables and long-term follow-up of 42 adult patients. Transplantation 71:8, 2001. lymphoma, leg type: Clinicopathologic features and prognostic analysis in 60 cases.
144. Choquet S, Leblond V, Herbrecht R, et al: Efficacy and safety of rituximab in B-cell Arch Dermatol 143:9, 2007.
post-transplantation lymphoproliferative disorders: Results of a prospective multicen- 157. Grange F, Maubec E, Bagot M, et al: Treatment of cutaneous B-cell lymphoma, leg
ter phase 2 study. Blood 107:8, 2006. type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol
145. Trappe R, Riess H, Babel N, et al: Salvage chemotherapy for refractory and relapsed 145:3, 2009.
posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent 158. Kodama K, Massone C, Chott A, et al: Primary cutaneous large B-cell lymphomas:
rituximab. Transplantation 83:7, 2007. Clinicopathologic features, classification, and prognostic factors in a large series of
146. Swinnen LJ, LeBlanc M, Grogan TM, et al: Prospective study of sequential reduction in patients. Blood 106:7, 2005.
immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation 159. Beltran B, Castillo J, Salas R, et al: ALK-positive diffuse large B-cell lymphoma: Report
lymphoproliferative disorder. Transplantation 86:2, 2008. of four cases and review of the literature. J Hematol Oncol 2:11, 2009.
147. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C: T-cell/histiocyte-rich large B-cell 160. Reichard KK, McKenna RW, Kroft SH: ALK-positive diffuse large B-cell lymphoma:
lymphoma: A distinct clinicopathologic entity. J Clin Oncol 20:5, 2002. Report of four cases and review of the literature. Mod Pathol 20:3, 2007.
148. Abramson JS: T-cell/histiocyte-rich B-cell lymphoma: Biology, diagnosis, and manage-
ment. Oncologist 11:4, 2006.

Kaushansky_chapter 98_p1625-1640.indd 1640 9/18/15 11:42 PM